High-Precision Radiotherapy Preserves Neurocognitive and Endocrine Function with Favorable Impact on Survival in Pediatric and Adolescent Low-Grade Gliomas

Background Pediatric and adolescent low-grade gliomas (pLGGs) have excellent long-term survival, making treatment-related morbidity an important consideration. Radiotherapy (RT) remains an important modality for tumor control, particularly in progressive/refractory settings. This randomized trial subset analysis compares conventional RT (ConvRT) and Stereotactic Conformal RT (SCRT) to assess the clinical benefits of advanced techniques. Methods The pLGG subset comprised 102 patients (SCRT:56; ConvRT:46) and was analyzed with modified intention-to-treat approach to assess neurocognitive and endocrine function, overall survival (OS), progression-free survival (PFS) and local control (LC). Neurocognitive outcomes were measured from baseline to five years post-RT using age-appropriate Wechsler scales, with trends analyzed by Linear Mixed-Effects model. Results Median age was 12 years (IQR: 8–18). At a median follow-up of 174.5 months (IQR: 86.8–219.8), 15-year LC was 91.3% (95% CI, 85.7–97.2), and 15-year OS was 83.9% (95%CI, 76.4—92.1). Improved OS favoured SCRT (92.2% vs ConvRT 73.4%, adjusted HR,0.29; 95%CI, 0.09–0.96; P = 0.043), and pilocytic astrocytoma histology (p = 0.014). PFS numerically favored SCRT (p = 0.064), with no difference in LC (p = 0.25). SCRT showed significantly better full-scale-IQ trajectory (+1.82 points/year, p = 0.033) and improved performance quotient (+2.15,p=0.043). At 5 years, SCRT significantly reduced cumulative incidence of cognitive decline (≥10-point IQ drop), compared with ConvRT (30.6% vs 59.5%; SHR=0.43, p = 0.018), and neuroendocrine dysfunction (33.1% vs 56.2%; SHR=0.51, p = 0.027). ConvRT patients experienced higher cumulative incidence of vascular events (15.8% vs 2.9%, p = 0.09). Conclusion SCRT preserves neurocognitive and endocrine function with favourable long-term survival in pLGG, while maintaining high tumor control, supporting the use of high-precision RT techniques when indicated.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology Pediatrics
Published
2026-11-19
DOI
https://doi.org/10.1093/neuped/wuag064
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

High-Precision Radiotherapy Preserves Neurocognitive and Endocrine Function with Favorable Impact on Survival in Pediatric and Adolescent Low-Grade Gliomas

Tejpal Gupta, Rakesh Jalali, Archya Dasgupta, Savita S. Goswami et al.
Neuro-Oncology Pediatrics
Glioma Diagnosis and Treatment
article

High-Precision Radiotherapy Preserves Neurocognitive and Endocrine Function with Favorable Impact on Survival in Pediatric and Adolescent Low-Grade Gliomas

Tejpal Gupta, Rakesh Jalali, Archya Dasgupta, Savita S. Goswami, Abhishek Chatterjee, Jayant Sastri Goda, Debnarayan Dutta, Uday Krishna, Nidhi Jain, Suman Ghosh
article en

Abstract

Background Pediatric and adolescent low-grade gliomas (pLGGs) have excellent long-term survival, making treatment-related morbidity an important consideration. Radiotherapy (RT) remains an important modality for tumor control, particularly in progressive/refractory settings. This randomized trial subset analysis compares conventional RT (ConvRT) and Stereotactic Conformal RT (SCRT) to assess the clinical benefits of advanced techniques. Methods The pLGG subset comprised 102 patients (SCRT:56; ConvRT:46) and was analyzed with modified intention-to-treat approach to assess neurocognitive and endocrine function, overall survival (OS), progression-free survival (PFS) and local control (LC). Neurocognitive outcomes were measured from baseline to five years post-RT using age-appropriate Wechsler scales, with trends analyzed by Linear Mixed-Effects model. Results Median age was 12 years (IQR: 8–18). At a median follow-up of 174.5 months (IQR: 86.8–219.8), 15-year LC was 91.3% (95% CI, 85.7–97.2), and 15-year OS was 83.9% (95%CI, 76.4—92.1). Improved OS favoured SCRT (92.2% vs ConvRT 73.4%, adjusted HR,0.29; 95%CI, 0.09–0.96; P = 0.043), and pilocytic astrocytoma histology (p = 0.014). PFS numerically favored SCRT (p = 0.064), with no difference in LC (p = 0.25). SCRT showed significantly better full-scale-IQ trajectory (+1.82 points/year, p = 0.033) and improved performance quotient (+2.15,p=0.043). At 5 years, SCRT significantly reduced cumulative incidence of cognitive decline (≥10-point IQ drop), compared with ConvRT (30.6% vs 59.5%; SHR=0.43, p = 0.018), and neuroendocrine dysfunction (33.1% vs 56.2%; SHR=0.51, p = 0.027). ConvRT patients experienced higher cumulative incidence of vascular events (15.8% vs 2.9%, p = 0.09). Conclusion SCRT preserves neurocognitive and endocrine function with favourable long-term survival in pLGG, while maintaining high tumor control, supporting the use of high-precision RT techniques when indicated.

Neuro-Oncology Pediatrics
Homi Bhabha National Institute (IN), Tata Memorial Hospital (IN)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon